Measles and rubella elimination country profile
Turkey

Measles elimination status

2015 endemic
2016 interrupted

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

Rubella elimination status

2015 endemic
2016 endemic

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

National plan of action

Does the country have a national plan of action?
ND

Is it updated?
ND

Source: Measles and rubella elimination Annual Status Update report, 2016

Demographic information, 2016

<table>
<thead>
<tr>
<th>Total population</th>
<th>79 622 062</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1 year old</td>
<td>1 275 547</td>
</tr>
<tr>
<td>&lt; 5 years old</td>
<td>6 830 574</td>
</tr>
</tbody>
</table>


Measles and rubella immunization schedule, 2016

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Schedule</th>
<th>Year of introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCV1</td>
<td>MMR</td>
<td>12 months</td>
</tr>
<tr>
<td>MCV2</td>
<td>MMR</td>
<td>6 years</td>
</tr>
</tbody>
</table>

MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; MMR = measles-mumps-rubella-containing vaccine; RCV = rubella-containing vaccine


Measles vaccination in school

Yes

Source: Measles and rubella elimination Annual Status Update report, 2016

Definition used for an outbreak

2 or more laboratory-confirmed cases which are temporally related (with dates of rash onset occurring between 7 and 18 days apart for measles, and between 12 and 46 days apart for rubella) and epidemiologically or virologically linked, or both

Source: Measles and rubella elimination Annual Status Update report, 2016

Measles and rubella cases and immunization coverage, 2007–2016

Source: Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)
MCV1 = first dose measles-containing vaccine
MCV2 = second dose measles-containing vaccine

Confirmed measles cases by month of onset, 2012–2016

Source: CSID2 2016
Measles and rubella elimination country profile
Turkey

Measles cases by first subnational level, 2016

Measles cases by first subnational level, 2016

Measles genotypes by first subnational level, 2016

Measles genotypes by first subnational level, 2016

Sources of infection, 2016

Supplementary immunization activities

Information on CRS, 2016

No cases reported

Source: Measles and rubella elimination Annual Status Update report, 2016

©WHO 2018
Measles and rubella elimination country profile
Turkey

Measles incidence, epidemiologic and virologic characteristics, 2012-2016

<table>
<thead>
<tr>
<th>Year</th>
<th>Suspected measles cases</th>
<th>Confirmed measles cases</th>
<th>Discarded as non-measles</th>
<th>Measles incidence</th>
<th>Genotypes detected</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>1267</td>
<td>343</td>
<td>6</td>
<td>349</td>
<td>918</td>
</tr>
<tr>
<td>2013</td>
<td>17 809</td>
<td>7 389</td>
<td>16</td>
<td>7 405</td>
<td>10 404</td>
</tr>
<tr>
<td>2014</td>
<td>4 876</td>
<td>562</td>
<td>3</td>
<td>565</td>
<td>4 311</td>
</tr>
<tr>
<td>2015</td>
<td>3 492</td>
<td>342</td>
<td>0</td>
<td>342</td>
<td>3 150</td>
</tr>
<tr>
<td>2016</td>
<td>2 217</td>
<td>9</td>
<td>0</td>
<td>9</td>
<td>2 208</td>
</tr>
</tbody>
</table>

Source: Measles and rubella elimination Annual Status Update report, 2012-2016, and internal communication from country. Incidence calculated per 1 million population. ND = Data not available; NA = Not applicable.

Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

<table>
<thead>
<tr>
<th>Year</th>
<th>Suspected rubella cases</th>
<th>Confirmed measles cases</th>
<th>Discarded as non-rubella</th>
<th>Rubella incidence</th>
<th>Genotypes detected</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>ND</td>
<td>41</td>
<td>0</td>
<td>0</td>
<td>41</td>
</tr>
<tr>
<td>2013</td>
<td>ND</td>
<td>81</td>
<td>0</td>
<td>0</td>
<td>81</td>
</tr>
<tr>
<td>2014</td>
<td>136</td>
<td>39</td>
<td>0</td>
<td>0</td>
<td>39</td>
</tr>
<tr>
<td>2015</td>
<td>135</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>2016</td>
<td>300</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>

Source: Measles and rubella elimination Annual Status Update report, 2012-2016, and internal communication from country. Incidence calculated per 1 million population. ND = Data not available; NA = Not applicable.

RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) commends the National Verification Committee (NVC), national health authorities and public health system on interruption of endemic measles transmission in Turkey. The RVC commends Turkey on immunization activities targeting high-risk populations, including migrants and refugees, and on initiating rubella virus genotyping in 2016. The RVC urges the national health authorities and public health system to strengthen activities in line with WHO resolutions and guidelines to achieve and document elimination of rubella as well.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

Surveillance performance indicators and targets

a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
b. % cases with adequate laboratory investigation: ≥ 80%
c. % origin of infection known: ≥ 80%
d. Rate of viral detection: ≥ 80%